Skip to content

Cogent Biosciences, Inc. COGT Book value per share

Book value per share at other companies

Pfizer logo
PfizerPFE
$15.72-0.6%
Amgen logo
AmgenAMGN
$16.89+47.2%
Incyte logo
IncyteINCY
$27.19+46.9%
Tango Therapeutics logo
Tango TherapeuticsTNGX
$2.73+80.4%
CG Oncology logo
CG OncologyCGON
$12.92+39.6%
Scholar Rock logo
Scholar RockSRRK
$2.17-22.3%

Other financials

Income statement

See full
Operating income-$103.6M-38.3%
Net income-$97.4M-35.2%
EPS (diluted)-$0.53-1.9%

Balance sheet

See full
Cash & equivalents$241.2M+91.4%
Total debt$15.5M-9.4%
Total equity$607.7M+177%
Total assets$903.0M+218%

Cash flow

See full
Operating cash flow-$86.9M-30.6%
CapEx$449.0K-17.9%
Free cash flow-$87.3M-30.2%

Valuation

See full
Market cap$5.9B+816%
Enterprise value$5.68B+951%
P/S749.8×

Profitability

See full
Operating margin-1,044.3%
Net margin-950.4%
FCF margin-184.7%

Returns & leverage

See full
Return on equity-85.7%+1.7pp
Debt / equity-0.1×
Current ratio15.1×+10.0×

Where this comes from

Calculated from Cogent Biosciences, Inc.’s reported figures.

Based on the most recent quarter.

The official record: Cogent Biosciences, Inc.’s 10-Q, filed May 5, 2026, on SEC EDGAR. View the filing →

Ask your AI about Cogent Biosciences, Inc.'s book value per share.

Connect your AI assistant and compare it to peers, right in your chat.

Connect your AI
Harbor at dusk
Claude

Questions, answered.

What is Cogent Biosciences, Inc.'s book value per share?
Cogent Biosciences, Inc. (COGT) reported book value per share of $3.75 in Q1 2026.
How has Cogent Biosciences, Inc.'s book value per share changed year-over-year?
Cogent Biosciences, Inc.'s book value per share increased by 93.9% year-over-year, from $1.93 to $3.75.
What is the long-term trend for Cogent Biosciences, Inc.'s book value per share?
Over 5 years (2020 to 2025), Cogent Biosciences, Inc.'s book value per share has grown at a -25.3% compound annual growth rate (CAGR), from $21.18 to $4.94.
What does book value per share mean?
Shareholders' equity divided by diluted shares outstanding at the quarter end. The accounting (book) value attributable to each share.